Ceftolozane/Tazobactam + Meropenem
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Urinary Tract Infection
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Trial Timeline
Apr 26, 2018 → Dec 3, 2020
NCT ID
NCT03230838About Ceftolozane/Tazobactam + Meropenem
Ceftolozane/Tazobactam + Meropenem is a phase 2 stage product being developed by Merck for Complicated Urinary Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03230838. Target conditions include Complicated Urinary Tract Infection, Pyelonephritis.
What happened to similar drugs?
4 of 20 similar drugs in Complicated Urinary Tract Infection were approved
Approved (4) Terminated (3) Active (15)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03230838 | Phase 2 | Completed |
| NCT02070757 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Urinary Tract Infection